<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02036489</url>
  </required_header>
  <id_info>
    <org_study_id>LAL-RI/2008</org_study_id>
    <nct_id>NCT02036489</nct_id>
  </id_info>
  <brief_title>Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Understand the dynamics of elimination of MRD in adult patients with standard-risk LAL&#xD;
      treated with a pediatric protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction therapy is administered. Patients experiencing slow response (&gt; 10 % blasts in the&#xD;
      15th mo of treatment) were included in the LAL -AR -03 protocol, on the arm of intensified&#xD;
      induction. Those who do not reach the RC will be excluded from the study and will be treated&#xD;
      according to the protocol LAL-AR/03 , which will be incorporated receiving blocks&#xD;
      consolidation. All patients in CR consolidation treatment (1 and 2 ) followed reinducciones&#xD;
      maintenance (maintenance -1 ) to complete the first year of treatment and maintenance without&#xD;
      reinducciones (maintenance -2 ) to complete two years from the RC will be administered . If&#xD;
      after union persistent high levels of ER ( &gt; 0.05 %) and this reappears later during&#xD;
      maintenance therapy the patient will be excluded from the study and will be treated according&#xD;
      to the protocol of high risk ( PETHEMA LAL-AR/03 ) . In case of persistent high levels of ER&#xD;
      patients after consolidation will consolidate blocks PETHEMA LAL-AR/03 protocol followed by&#xD;
      allogeneic HSCT . If the ER reappears during maintenance treatment the patient will receive&#xD;
      an allogeneic HSCT , Standby thereof, may be administered one or two blocks consolidation of&#xD;
      LAL -AR -03 protocol.&#xD;
&#xD;
      To allow time to better characterize the LLA and thus ensure proper inclusion of patients in&#xD;
      the study recommends administering a prephase with :&#xD;
&#xD;
      - Prednisone ( PDN) 60 mg/m2 po or iv through characterization of LAL with a maximum of 7&#xD;
      days.&#xD;
&#xD;
      intrathecal chemotherapy&#xD;
&#xD;
        -  Methotrexate (MTX ) : 12 mg&#xD;
&#xD;
        -  ARA - C: 30 mg&#xD;
&#xD;
        -  Hydrocortisone 20 mg&#xD;
&#xD;
      The LAL meeting the inclusion criteria, the study may continue&#xD;
&#xD;
      Induction chemotherapy&#xD;
&#xD;
        -  Vincristine (VCR ) 1.5 mg/m2 ( maximum dose 2 mg ) iv on days 1 and 8.&#xD;
&#xD;
        -  daunorubicin (DNR ) 30 mg/m2 iv on days 1 and 8.&#xD;
&#xD;
        -  Prednisone ( PDN ): 60 mg/m2 night , i.v. or p.o , 1-14 days&#xD;
&#xD;
      Study of bone marrow at day +14&#xD;
&#xD;
        -  Less than 10% blasts ( by morphology) or hypocellular bone marrow&#xD;
&#xD;
        -  Vincristine (VCR ) 1.5 mg/m2 ( maximum dose 2 mg) iv 15 and 22&#xD;
&#xD;
        -  daunorubicin (DNR ) 30 mg/m2 i.v 15 and 22&#xD;
&#xD;
        -  L -asparaginase ( L -ASA ) of E. coli ( Kidrolase ® ) : 10,000 IU/m2 , iv , 16-20 ,&#xD;
           23-27 .&#xD;
&#xD;
        -  1,000 mg/m2 cyclophosphamide , i.v. day 36&#xD;
&#xD;
        -  Prednisone ( PDN) :&#xD;
&#xD;
        -  60 mg/m2 per day, i.v or p.o , days 15-27&#xD;
&#xD;
        -  30 mg/m2 per day, i.v or p.o , days 28-35&#xD;
&#xD;
        -  Equal to or more than 10 % blasts ( by morphology)&#xD;
&#xD;
        -  Step PETHEMA protocol LAL-AR/2003&#xD;
&#xD;
      Intrathecal chemotherapy&#xD;
&#xD;
        -  Methotrexate (MTX ) 12 mg days 1 and 29&#xD;
&#xD;
        -  ARA- C: 30 mg days 1 and 29&#xD;
&#xD;
        -  Hydrocortisone 20 mg days 1 and 29&#xD;
&#xD;
      Evaluation at the end of induction (day 28 or when a finding hemoperiférica recovery)&#xD;
&#xD;
        -  Patients RC : consolidation -1&#xD;
&#xD;
        -  Patients without RC : excluded. Step PETHEMA LAL-AR/2003 protocol .&#xD;
&#xD;
      Study of the ER at the end of induction. Molecular response was considered if the ER is &lt;&#xD;
      0.01 %. Although a molecular response is not achieved , the patient will remain in the&#xD;
      protocol if you have standard response at day 14 and is in CR at day 28 .&#xD;
&#xD;
      Consolidation treatment -1 These cycles include known cytostatics LAL activity against at&#xD;
      intermediate or high doses. This phase of treatment as possible to begin two weeks of the&#xD;
      administration of the last dose of cytostatic induction phase . The patient should have a WBC&#xD;
      count &gt; 3x109 / L (granulocytes &gt; 1.5 x 109 / L ) and platelets &gt; 100x109 / L.&#xD;
&#xD;
      Mercaptopurine ( MP ) 50 mg/m2 , po, days 1-7 , 28-35 and 56-63 MTX : 3 g/m2 iv , in 24 hours&#xD;
      , day 1, 28 and 56 . For administration, and rescue treatment should be followed the rules&#xD;
      specified below .&#xD;
&#xD;
      VP -16 100 mg/m2 ( infusion 1 hour), 14-15 and 42-43 ARA- C 500 mg/m2 iv every 12 hours , 3&#xD;
      hours , 14-15 and 42-43 . Intrathecal Chemotherapy or Methotrexate ( MTX ) 12 mg on days 1,&#xD;
      28 and 56 or ARA- C: 30 mg days 1, 28 and 56 or Hydrocortisone 20 mg days 1, 28 and 56&#xD;
&#xD;
      Treatment consolidation-2/reinduction It consists of a cycle similar to the induction&#xD;
      chemotherapy . It will start if possible within one week of completion of the last dose of&#xD;
      mercaptopurine in the previous cycle (thus, from the 18th week of the start of treatment) .&#xD;
&#xD;
      Dexamethasone (DXM ) :&#xD;
&#xD;
      or 10 mg/m2 per day, p.o or i.v 1-14 days to 5 mg/m2 night , p.o or i.v., day 15 to 21 VCR&#xD;
      1.5 mg/m2 , i.v. , days 1, 8 and 15 DNR : 30 mg/m2 , i.v. , 1, 2 , 8 and 9 CFM and 600 mg/m2&#xD;
      day , i.v. , days 1 and 15 L -ASA E. coli ( Kidrolase ® ) : 10,000 IU/m2 i.m. or i.v., on&#xD;
      days 1-4 and 15-18 .&#xD;
&#xD;
      Intrathecal Chemotherapy or methotrexate (MTX ) 12 mg days 1 and 15 or ARA- C: 30 mg days 1&#xD;
      and 15 or Hydrocortisone 20 mg days 1 and 15&#xD;
&#xD;
      Evaluation of ER at the end of the consolidation A cytofluorometric study fee is mo If the ER&#xD;
      is &gt; 0.05 % (tested on two separate occasions 15 days ) the patient will go to high-risk&#xD;
      protocol ( PETHEMA LAL-AR/2003 ) .&#xD;
&#xD;
      If ER &lt; 0.05 % the patient continue the protocol.&#xD;
&#xD;
      Maintenance treatment with 1 reinducciones It will consist of continuous administration of&#xD;
      chemotherapy ( mercaptopurine and methotrexate ) with reinducciones up to a year from the&#xD;
      start of treatment. It lasts therefore between approximately 22 and 52 weeks of treatment.&#xD;
&#xD;
      Continuous Chemotherapy&#xD;
&#xD;
        -  MP 50 mg/m2 per day, p.o&#xD;
&#xD;
        -  MTX 20 mg/m2 per week , i.m. Reinducciones&#xD;
&#xD;
        -  VCR 1.5 mg/m2 ( maximum dose 2 mg) , iv , day 1.&#xD;
&#xD;
        -  PDN 60 mg/m2 night , i.v. or p.o , days 1-7&#xD;
&#xD;
        -  L - ASA E. coli ( Kidrolase ® ) : 20,000 IU/m2 i.m. or i.v. , day 1.&#xD;
&#xD;
        -  Intrathecal Chemotherapy Methotrexate (MTX ) 12 mg 1st ARA- C: 30 mg 1st Hydrocortisone&#xD;
           20 mg Day 1&#xD;
&#xD;
      During the week of administration of each cycle of chemotherapy reinduction continuous&#xD;
      suspended.&#xD;
&#xD;
      Evaluation after the fourth reinduction . Immunophenotypic study of a new bone marrow will be&#xD;
      made&#xD;
&#xD;
        -  If ER is &lt; 0.01 % , subsequent reinducciones are suspended and continues only with&#xD;
           continuous chemotherapy until week 52 , at which point it switches to maintenance -2.&#xD;
&#xD;
        -  If ER between 0.05% and 0.01% , the reinducciones 5 was administered to 8&#xD;
&#xD;
        -  If ER &gt; 0.05 % (tested on two separate occasions 15 days ) the patient will go to&#xD;
           high-risk protocol ( PETHEMA LAL-AR/2003 ) .&#xD;
&#xD;
      Treatment Support 2 It consisitirá in continuous administration of chemotherapy (&#xD;
      mercaptopurine, and methotrexate ) to complete two years in continuous complete remission .&#xD;
&#xD;
        -  MP 50 mg/m2 per day, p.o&#xD;
&#xD;
        -  MTX 20 mg/m2 per week , i.m. Throughout the maintenance treatment should seek to retain&#xD;
           WBC counts between 2.5 and 5x109 / L and platelet counts above 120x109 / L. If these&#xD;
           lower limits should be reduced is decreased by 20 % doses of MP and MTX. If the numbers&#xD;
           of leukocytes exceed 5x109 / L will increase by 20 % the dose of MP (50 to 60 mg/m2 )&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2008</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of treatment in adulta with standard risk acute lymphoblastic leukemia</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Acute Lymphobkastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Induction and consolidation treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <arm_group_label>Induction and consolidation treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <arm_group_label>Induction and consolidation treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Induction and consolidation treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-asparaginase</intervention_name>
    <arm_group_label>Induction and consolidation treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclophosphamide</intervention_name>
    <arm_group_label>Induction and consolidation treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metotrexate</intervention_name>
    <arm_group_label>Induction and consolidation treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARA-C</intervention_name>
    <arm_group_label>Induction and consolidation treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hidrocortisone</intervention_name>
    <arm_group_label>Induction and consolidation treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <arm_group_label>Induction and consolidation treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP-16</intervention_name>
    <arm_group_label>Induction and consolidation treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexametasone</intervention_name>
    <arm_group_label>Induction and consolidation treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adults (age&gt; 15 years) with ALL standard risk previously untreated. The LAL standard risk&#xD;
        is defined by all of the following criteria:&#xD;
&#xD;
          -  Age less than 30 years&#xD;
&#xD;
          -  WBC &lt;25x109 / L&#xD;
&#xD;
          -  Absence of cytogenetic alterations that misbehave forecast or t (9, 22) or&#xD;
             demonstration of BCR-ABL rearrangement or alterations in 11q23, or demonstration&#xD;
             ALL1-AF4 rearrangement (MLL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        LAL L3 type mature phenotype B (sIg +) or with cytogenetic abnormalities characteristic of&#xD;
        Burkitt LAL (t [8, 14], t [2, 8], t [8, 22]). For these patients have the BURKIMAB study.&#xD;
&#xD;
          -  LAL Ph (BCR-ABL) positive. These patients should be treated with imatinib associated&#xD;
             with chemotherapy.&#xD;
&#xD;
          -  Biphenotypic acute leukemias and bilinear. For these patients treatment is recommended&#xD;
             LAM own guidelines.&#xD;
&#xD;
          -  Acute undifferentiated leukemias. For these patients treatment is recommended LAM own&#xD;
             guidelines.&#xD;
&#xD;
          -  Patients with a history of coronary artery disease, valvular or hypertensive heart&#xD;
             disease.&#xD;
&#xD;
          -  Patients with chronic liver disease.&#xD;
&#xD;
          -  Patients with chronic respiratory failure.&#xD;
&#xD;
          -  Renal failure not due to the LAL.&#xD;
&#xD;
          -  Severe neurological disorders, not due to the LAL.&#xD;
&#xD;
          -  General State concerned (grades 3 and 4 WHO scale), not attributable to the LAL.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2014</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

